Gubra A/S
CSE:GUBRA
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
114
726
|
Price Target |
|
We'll email you a reminder when the closing price reaches DKK.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one GUBRA stock under the Base Case scenario is 61.16 DKK. Compared to the current market price of 470 DKK, Gubra A/S is Overvalued by 87%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Gubra A/S
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for GUBRA cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Gubra A/S
Balance Sheet Decomposition
Gubra A/S
Current Assets | 492.3m |
Cash & Short-Term Investments | 446.9m |
Receivables | 39.7m |
Other Current Assets | 5.6m |
Non-Current Assets | 118.5m |
Long-Term Investments | 4.6m |
PP&E | 96.1m |
Intangibles | 13.8m |
Other Non-Current Assets | 3.9m |
Current Liabilities | 68m |
Accounts Payable | 14.8m |
Other Current Liabilities | 53.2m |
Non-Current Liabilities | 78.9m |
Long-Term Debt | 78m |
Other Non-Current Liabilities | 848k |
Earnings Waterfall
Gubra A/S
Revenue
|
223.8m
DKK
|
Cost of Revenue
|
-92.4m
DKK
|
Gross Profit
|
131.5m
DKK
|
Operating Expenses
|
-182.4m
DKK
|
Operating Income
|
-50.9m
DKK
|
Other Expenses
|
4.4m
DKK
|
Net Income
|
-46.5m
DKK
|
Free Cash Flow Analysis
Gubra A/S
DKK | |
Free Cash Flow | DKK |
GUBRA Profitability Score
Profitability Due Diligence
Gubra A/S's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
Score
Gubra A/S's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
GUBRA Solvency Score
Solvency Due Diligence
Gubra A/S's solvency score is 74/100. The higher the solvency score, the more solvent the company is.
Score
Gubra A/S's solvency score is 74/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
GUBRA Price Targets Summary
Gubra A/S
According to Wall Street analysts, the average 1-year price target for GUBRA is 887.4 DKK with a low forecast of 878.7 DKK and a high forecast of 913.5 DKK.
Dividends
Current shareholder yield for GUBRA is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Gubra ApS operates as biotechnology company. The Company’s operations are anchored around its advanced technology platforms and utilization of automation, robotization and digitalization, including machine learning (ML) and artificial intelligence (AI). The firm's business activity are divided into two segments: The CRO Segment offers specialized profitable pre-clinical contract research services at attractive margins within metabolic and fibrotic disease areas such as diabetes, obesity, chronic kidney disease; and The Discovery and Partnership Segment is based on an internal target and drug discovery engine for identification and design of peptide-based drug partnering candidates within metabolic and fibrotic diseases.
Officers
The intrinsic value of one GUBRA stock under the Base Case scenario is 61.16 DKK.
Compared to the current market price of 470 DKK, Gubra A/S is Overvalued by 87%.